Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...
Asthma is an inflammatory disease typified by airway hyperreactivity and obstruction-producing airway resistance with a reduction in air flow. [1] The mainstay of treatment of acute asthma in children ...
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study Various pharmacologic strategies have been ...
The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...
Paricalcitol 2mcg/mL, 5mcg/mL; soln for IV inj; contains alcohol. Give as IV bolus inj during dialysis. Initially 0.04–0.1mcg/kg (2.8–7mcg) no more often than every other day; may increase in ...
People aged 16 or over at high risk of severe illness or death from sepsis in acute hospital settings have an intravenous fluid bolus within 1 hour of risk being identified, unless contraindicated.
antithrombin III [human] Thrombate III inj Hereditary antithrombin III (AT-III) deficiency in surgical or obstetrical procedures and thromboembolism Infuse over 10–20mins. Dose (units required) = ...
HELSINKI, Finland—Patients with acute ischemic stroke caused by a large-vessel occlusion (LVO) who are undergoing endovascular thrombectomy fare better when intravenous tenecteplase (TNK) is ...
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results